Loading...

Imagion Biosystems

ASX:IBX
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IBX
ASX
A$10M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Imagion Biosystems Limited operates in the field of non-invasive detection of specific solid tumour cancers by use of magnetic nanoparticles. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Imagion Biosystems has significant price volatility in the past 3 months.
IBX Share Price and Events
7 Day Returns
7.7%
ASX:IBX
2.3%
AU Medical Equipment
1.8%
AU Market
1 Year Returns
-57.6%
ASX:IBX
-1.1%
AU Medical Equipment
6%
AU Market
IBX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Imagion Biosystems (IBX) 7.7% 12% -20% -57.6% - -
AU Medical Equipment 2.3% 4% -0.1% -1.1% 44.3% 109.3%
AU Market 1.8% 3.9% 7.8% 6% 20.5% 8.4%
1 Year Return vs Industry and Market
  • IBX underperformed the Medical Equipment industry which returned -1.1% over the past year.
  • IBX underperformed the Market in Australia which returned 6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Imagion Biosystems undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Imagion Biosystems. This is due to cash flow or dividend data being unavailable. The share price is A$0.028.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Imagion Biosystems's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Imagion Biosystems's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:IBX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.04
ASX:IBX Share Price ** ASX (2019-04-26) in AUD A$0.03
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 34.76x
Australia Market PE Ratio Median Figure of 543 Publicly-Listed Companies 16.33x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Imagion Biosystems.

ASX:IBX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:IBX Share Price ÷ EPS (both in AUD)

= 0.03 ÷ -0.04

-0.74x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Imagion Biosystems is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Imagion Biosystems is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Imagion Biosystems's expected growth come at a high price?
Raw Data
ASX:IBX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.74x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.39x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Imagion Biosystems, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Imagion Biosystems's assets?
Raw Data
ASX:IBX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.01
ASX:IBX Share Price * ASX (2019-04-26) in AUD A$0.03
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.77x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:IBX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:IBX Share Price ÷ Book Value per Share (both in AUD)

= 0.03 ÷ 0.01

2.34x

* Primary Listing of Imagion Biosystems.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Imagion Biosystems is good value based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Imagion Biosystems's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Imagion Biosystems has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Imagion Biosystems expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Imagion Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.1%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Imagion Biosystems expected to grow at an attractive rate?
  • Unable to compare Imagion Biosystems's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Imagion Biosystems's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Imagion Biosystems's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:IBX Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.8%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:IBX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:IBX Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -7 -8
2018-09-30 0 -7 -8
2018-06-30 0 -8 -8
2018-03-31 0 -7 -8
2017-12-31 0 -7 -8
2016-12-31 0 -3 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Imagion Biosystems is high growth as no earnings estimate data is available.
  • Unable to determine if Imagion Biosystems is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:IBX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Imagion Biosystems Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:IBX Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.04
2018-09-30 -0.03
2018-06-30 -0.04
2018-03-31 -0.04
2017-12-31 -0.05
2016-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Imagion Biosystems will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of IBX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Imagion Biosystems's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Imagion Biosystems's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Imagion Biosystems's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Imagion Biosystems has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Imagion Biosystems performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Imagion Biosystems's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Imagion Biosystems does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Imagion Biosystems's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Imagion Biosystems's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Imagion Biosystems's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Imagion Biosystems Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:IBX Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.37 -8.34 5.64 3.30
2018-09-30 0.36 -8.10 5.60 2.90
2018-06-30 0.35 -7.86 5.57 2.51
2018-03-31 0.34 -7.83 5.20 2.33
2017-12-31 0.34 -7.79 4.84 2.16
2016-12-31 0.00 -12.41 0.51 6.02
2015-12-31 0.01 -4.40 0.25 3.88
2014-12-31 0.01 -2.51 0.09 2.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Imagion Biosystems has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Imagion Biosystems has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Imagion Biosystems improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Imagion Biosystems's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Imagion Biosystems has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Imagion Biosystems's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Imagion Biosystems's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Imagion Biosystems is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Imagion Biosystems's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Imagion Biosystems's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 90.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Imagion Biosystems Company Filings, last reported 3 months ago.

ASX:IBX Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 3.87 0.05 4.37
2018-09-30 3.87 0.05 4.37
2018-06-30 3.74 0.07 3.61
2018-03-31 3.74 0.07 3.61
2017-12-31 6.95 0.08 6.87
2016-12-31 -14.63 13.93 0.03
2015-12-31 -8.86 9.49 0.39
2014-12-31 -3.97 4.19 0.16
  • Imagion Biosystems's level of debt (1.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Imagion Biosystems's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Imagion Biosystems has less than a year of cash runway based on current free cash flow.
  • Imagion Biosystems has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.2% each year.
X
Financial health checks
We assess Imagion Biosystems's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Imagion Biosystems has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Imagion Biosystems's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Imagion Biosystems dividends.
If you bought A$2,000 of Imagion Biosystems shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Imagion Biosystems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Imagion Biosystems's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:IBX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Imagion Biosystems has not reported any payouts.
  • Unable to verify if Imagion Biosystems's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Imagion Biosystems's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Imagion Biosystems has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Imagion Biosystems's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Imagion Biosystems afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Imagion Biosystems has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Imagion Biosystems's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bob Proulx
COMPENSATION A$639,179
AGE 60
CEO Bio

Mr. Robert Romeo Proulx, also known as Bob, has been the President and Chief Executive Officer at Imagion Biosystems, Inc. since January 12, 2015. Mr. Proulx's responsibilities include building Senior Scientific's core capabilities in nano-particle technology and expanding on the collaborations in place with the MD Anderson Cancer Center in Houston and The University of New Mexico Health Sciences Center, Albuquerque. Mr. Proulx serves as the President of Imagion at Manhattan Scientifics, Inc. He served as the President of Senior Scientific at Manhattan Scientifics, Inc. since January 2015. Mr. Proulx is a veteran business executive with more than 25 years of leadership experience for both private and public companies in the life science and diagnostic device markets. He served as the Chief Commercial Officer and General Manager of US Operations at SILICON BIOSYSTEMS S.p.A. and served as its President. Mr. Prolux has over 25 years’ experience bringing life science and medical device products through development and commercialization. He served as Vice President of Marketing & Sales at Nanogen, Inc., where he was responsible for worldwide corporate branding, product marketing and North American sales operations for it in vitro diagnostic products. Mr. Proulx served as Senior Vice President of Marketing of Ore Holdings, Inc since July 2003. From 2000 to July 2003, Mr. Proulx served as General Manager, Life Sciences of IGEN International, Inc. He is Executive Chairman of Imagion Biosystems, Inc. and has been its Director since December 06, 2016. Prior to 2000, Mr. Proulx held numerous management positions with Packard Instrument Company, Inc., a subsidiary of Packard Bioscience, a leading global provider of laboratory instruments and reagents. He held senior-level positions at Gene Logic Inc.;. and Bio-Tek Instruments, Inc. He has served on the board of directors of Semrock and PGXL Diagnostic Laboratories since 2009 until 2017 and has been a volunteer in the CONNECT Springboard Entrepreneurs in Residence program, helping nurture startups through early-stage business planning. Mr. Proulx holds an M.A. and B.A. from The State University of New York, Albany. He is a graduate of the Executive Management Program at The Pennsylvania State University Smeal College of Business.

CEO Compensation
  • Insufficient data for Bob to compare compensation growth.
  • Bob's remuneration is higher than average for companies of similar size in Australia.
Management Team

Bob Proulx

TITLE
Executive Chairman
COMPENSATION
A$639K
AGE
60

Brian Conn

TITLE
Chief Financial Officer
COMPENSATION
A$241K

Jovanka Naumoska

TITLE
Company Secretary & Non Executive Director
COMPENSATION
A$11K
TENURE
2.3 yrs

Marie Zhang

TITLE
Vice-President of Research & Pre- Clinical Dev
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Imagion Biosystems board of directors in years:

2.1
Average Tenure
64
Average Age
  • The average tenure for the Imagion Biosystems board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bob Proulx

TITLE
Executive Chairman
COMPENSATION
A$639K
AGE
60

Jovanka Naumoska

TITLE
Company Secretary & Non Executive Director
COMPENSATION
A$11K
TENURE
2.3 yrs

Mark Van Asten

TITLE
Non Executive Director
COMPENSATION
A$11K
TENURE
2.3 yrs

David Ludvigson

TITLE
Non Executive Director
COMPENSATION
A$11K
AGE
67
TENURE
2.1 yrs

John Hazle

TITLE
Chairman of Scientific Advisory Board & Non-Executive Director
TENURE
0.8 yrs

Mike Harsh

TITLE
Non-Executive Director
COMPENSATION
A$11K
AGE
64
TENURE
2.2 yrs

Bronwyn Le Grice

TITLE
Non Executive Director
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
30. Oct 18 Buy Robert Proulx Individual 24. Oct 18 24. Oct 18 117,500 A$0.04 A$4,700
X
Management checks
We assess Imagion Biosystems's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Imagion Biosystems has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Imagine Owning Imagion Biosystems (ASX:IBX) While The Price Tanked 66%

View our latest analysis for Imagion Biosystems. … Investors will be hoping that Imagion Biosystems can make progress and gain better traction for the business, before it runs low on cash. … Imagion Biosystems had net cash of just AU$3.0m when it last reported (December 2018).

Simply Wall St -

Could The Imagion Biosystems Limited (ASX:IBX) Ownership Structure Tell Us Something Useful?

If you want to know who really controls Imagion Biosystems Limited (ASX:IBX), then you'll have to look at the makeup of its share registry. … Generally speaking, as a company grows, institutions will increase their ownership. … Imagion Biosystems is not a large company by global standards.

Simply Wall St -

How Financially Strong Is Imagion Biosystems Limited (ASX:IBX)?

While small-cap stocks, such as Imagion Biosystems Limited (ASX:IBX) with its market cap of AU$9.80m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Imagion Biosystems Inc's (ASX:IBX) Single Biggest Risk For Investors

Additional cash raising may dilute the value of your shares, and since Imagion Biosystems is currently burning more cash than it is making, it’s likely the business will need funding for future growth. … View our latest analysis for Imagion Biosystems What is cash burn? … Not surprisingly, if Imagion Biosystems continues to ramp up expenditure at this rate for the upcoming year, it’ll likely need to come to market within the next few months, given the its current level of cash reserves.

Simply Wall St -

Has Imagion Biosystems Inc (ASX:IBX) Improved Earnings Growth In Recent Times?

After looking at Imagion Biosystems Inc's (ASX:IBX) latest earnings announcement (31 December 2017), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … Check out our latest analysis for Imagion Biosystems How Well Did IBX Perform? … ASX:IBX Income Statement Apr 23rd 18 We can further assess Imagion Biosystems's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Are Imagion Biosystems Inc's (ASX:IBX) Interest Costs Too High?

How does IBX’s operating cash flow stack up against its debt? … Moving onto cash from operations, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look. … Investors' risk associated with debt is virtually non-existent with IBX, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: Although IBX’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings.

Simply Wall St -

Should You Be Concerned About Imagion Biosystems Inc's (ASX:IBX) Investors?

Check out our latest analysis for Imagion Biosystems ASX:IBX Ownership_summary Feb 24th 18 Institutional Ownership Institutional investors transact in large blocks which can influence the momentum of stock prices, at least in the short-term, especially when there is a low level of public shares available on the market to trade. … Private Company Ownership Potential investors in IBX should also look at another important group of investors: private companies, with a stake of 11.83%, who are primarily invested because of strategic and capital gain interests. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: Institutional ownership level and composition in IBX is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

Have Investors Already Priced In Healthcare Growth For Imagion Biosystems Inc (ASX:IBX)?

Imagion Biosystems Inc (ASX:IBX), a A$20.38M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impacting the sector globally. … In this article, I’ll take you through the sector growth expectations, as well as evaluate whether Imagion Biosystems is lagging or leading its competitors in the industry. … Given the lack of analyst consensus in Imagion Biosystems’s outlook, we could potentially assume the stock’s growth rate broadly follows its healthcare equipment industry peers.

Simply Wall St -

Does Imagion Biosystems Inc (ASX:IBX) Need To Raise More Cash?

The single most important question to ask when you’re investing in a loss-making company is – will they need to raise cash again, and if so, when? … ASX:IBX Income Statement Jan 16th 18 When will Imagion Biosystems need to raise more cash? … This means that, if Imagion Biosystems continues to grow its opex at this rate, given how much money it currently has in the bank, it will actually need to raise capital again within the next couple of months!

Simply Wall St -

Who Are The Major Shareholders In Imagion Biosystems Inc (ASX:IBX)?

This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Institutional ownership in IBX is not at a level that would concern investors.

Simply Wall St -

Company Info

Description

Imagion Biosystems Limited operates in the field of non-invasive detection of specific solid tumour cancers by use of magnetic nanoparticles. The company engages in the research and development of its clinical phase lead product for the detection and staging of metastatic HER2 breast cancer. It also uses MagSense technology that is based on superparamagnetic relaxometry for early cancer detection, cancer staging, and therapeutic monitoring. The company was founded in 1996 and is based in Albuquerque, New Mexico.

Details
Name: Imagion Biosystems Limited
IBX
Exchange: ASX
Founded: 1996
A$9,682,284
322,742,824
Website: http://www.imagionbiosystems.com
Address: Imagion Biosystems Limited
800 Bradbury SE,
Suite 213,
Albuquerque,
New Mexico, 87106,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX IBX Ordinary Shares Australian Securities Exchange AU AUD 22. Jun 2017
Number of employees
Current staff
Staff numbers
0
Imagion Biosystems employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/26 10:35
End of day share price update: 2019/04/26 00:00
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.